SpringWorks Therapeutics (SWTX) Competitors $46.99 0.00 (0.00%) As of 07/1/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SWTX vs. ITCI, GMAB, RDY, QGEN, MRNA, ASND, VTRS, BPMC, BBIO, and VRNAShould you be buying SpringWorks Therapeutics stock or one of its competitors? The main competitors of SpringWorks Therapeutics include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. SpringWorks Therapeutics vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Qiagen Moderna Ascendis Pharma A/S Viatris Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share SpringWorks Therapeutics (NASDAQ:SWTX) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Does the media refer more to SWTX or ITCI? In the previous week, SpringWorks Therapeutics had 3 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 3 mentions for SpringWorks Therapeutics and 0 mentions for Intra-Cellular Therapies. SpringWorks Therapeutics' average media sentiment score of 0.54 beat Intra-Cellular Therapies' score of 0.00 indicating that SpringWorks Therapeutics is being referred to more favorably in the media. Company Overall Sentiment SpringWorks Therapeutics Positive Intra-Cellular Therapies Neutral Which has more risk & volatility, SWTX or ITCI? SpringWorks Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Is SWTX or ITCI more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to SpringWorks Therapeutics' net margin of -115.60%. Intra-Cellular Therapies' return on equity of -9.93% beat SpringWorks Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SpringWorks Therapeutics-115.60% -51.10% -43.80% Intra-Cellular Therapies -14.07%-9.93%-8.38% Which has better earnings & valuation, SWTX or ITCI? Intra-Cellular Therapies has higher revenue and earnings than SpringWorks Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpringWorks Therapeutics$191.59M18.48-$258.13M-$3.41-13.78Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Do institutionals & insiders hold more shares of SWTX or ITCI? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 7.8% of SpringWorks Therapeutics shares are held by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer SWTX or ITCI? SpringWorks Therapeutics currently has a consensus target price of $52.57, suggesting a potential upside of 11.88%. Intra-Cellular Therapies has a consensus target price of $109.70, suggesting a potential downside of 16.81%. Given SpringWorks Therapeutics' higher probable upside, research analysts clearly believe SpringWorks Therapeutics is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SpringWorks Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 SummaryIntra-Cellular Therapies beats SpringWorks Therapeutics on 11 of the 16 factors compared between the two stocks. Get SpringWorks Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SWTX vs. The Competition Export to ExcelMetricSpringWorks TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.54B$2.91B$5.55B$9.04BDividend YieldN/A2.44%5.22%4.00%P/E Ratio-13.7821.5627.6420.24Price / Sales18.48281.65418.75118.07Price / CashN/A42.7336.8958.10Price / Book7.267.518.035.67Net Income-$258.13M-$55.14M$3.18B$249.21M7 Day Performance0.02%4.61%2.93%3.28%1 Month Performance0.41%0.90%1.72%3.95%1 Year Performance27.79%5.40%34.39%20.98% SpringWorks Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SWTXSpringWorks Therapeutics1.3742 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230ITCIIntra-Cellular Therapies0.9449 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.5867 of 5 stars$20.66+0.8%$37.60+82.0%-20.1%$13.25B$3.12B11.742,682RDYDr. Reddy's Laboratories2.7025 of 5 stars$15.03-0.3%$16.95+12.8%-3.4%$12.55B$3.81B22.7727,811QGENQiagen4.0435 of 5 stars$48.07+0.6%$49.40+2.8%+21.0%$10.69B$1.98B120.525,765Dividend AnnouncementMRNAModerna4.3796 of 5 stars$27.59+1.6%$46.61+68.9%-74.2%$10.67B$3.24B-3.165,800Options VolumeASNDAscendis Pharma A/S3.5022 of 5 stars$172.60+0.2%$220.67+27.8%+28.2%$10.55B$393.54M-27.481,017News CoveragePositive NewsAnalyst ForecastVTRSViatris2.6598 of 5 stars$8.93-0.9%$10.40+16.5%-10.4%$10.48B$14.74B-2.8232,000BPMCBlueprint Medicines1.5556 of 5 stars$128.18+0.1%$128.06-0.1%+14.8%$8.28B$562.12M-51.89640BBIOBridgeBio Pharma4.6887 of 5 stars$43.18-3.7%$58.85+36.3%+69.7%$8.20B$221.90M-12.23400News CoverageInsider TradeAnalyst RevisionHigh Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.7753 of 5 stars$94.58+0.8%$101.10+6.9%+466.0%$8.05B$42.28M-47.2930News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Qiagen Competitors Moderna Competitors Ascendis Pharma A/S Competitors Viatris Competitors Blueprint Medicines Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SWTX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share SpringWorks Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SWTX Stock Alerts